Allogene Therapeutics Announces Participation in December Investor Conferences
SOUTH SAN FRANCISCO, Calif. , Nov. 19, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products…
Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence
ALLO-329 Induces Deep, Transient Depletion of CD19+ B Cells and CD70+ T Cells, and Reduction in IgG and IgM without Lymphodepletion in Humanized Murine Models Proprietary Dagger ® Technology Enables…
SC 13G/A: An amendment to the SC 13G filing
Allogene Therapeutics, Inc.
SC 13G/A: An amendment to the SC 13G filing
Allogene Therapeutics, Inc.
